FDA says hospitals may still have recalled heparin
Despite widespread publicity about heparin problems, several California hospitals were found to still have recalled heparin products in their supply chains, suggesting that the problem could still be an issue nationally, according to the FDA. The agency now has issued a request for hospitals and healthcare workers across the U.S. to search storage areas for possibly overlooked supplies of the drug, tainted versions of which have been blamed for 81 deaths. The recalled products were found last week during visits to California hospitals by the FDA and Baxter International, which made the batches that have since been recalled.
To learn more about the FDA's request:
- read this Modern Healthcare piece (reg. req.)
Related Articles:
Number of heparin-related deaths reported triples
Post-heparin, no oversight excuses
Comments
One would think that the legal counsel for the hospitals would be personally involved in checking the inventories. Seems a huge issue when the Chinese are killing our patients and the hospitals know the drug is dangerous in advance of administering it. Slam dunk for a multi-million dollar law suit by any junior attorney or paralegal.
Yes, Anonymous, it does seem like one heck of a risk. It's hard for me to imagine how hospitals could have let heparin flow into its systems, given the high profile given to the recall and deaths related to the tainted batches. Let's hope that the FDA's renewed warning comes soon enough.
-Anne Zieger, Editor
Post new comment
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies




